ClinicalTrials.gg
RecruitingNCT05410145Updated Sep 15, 2026

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

A Phase 1/2 interventional study of D3S-001 and Pembrolizumab in KRAS P.G12C, sponsored by D3 Bio (Wuxi) Co., Ltd. Recruiting at 52 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by D3 Bio (Wuxi) Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
442
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.

02

Conditions studied

  • KRAS P.G12C

Keywords

  • KRAS p.G12C
  • Mutation
  • advanced solid tumors
03

In context

Lead sponsor

D3 Bio (Wuxi) Co., Ltd is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have a or cytologically confirmed or locally advanced solid tumor which is progressing.
  • Subject must have documented KRAS p.G12C mutation identified within the last 5 years by a local test on tumor tissue or blood.
  • Subject must have per v1.1.
  • Subject must have (ECOG) performance status of 0 or 1.
  • Subject must have adequate organ and marrow function within the screening period.

Exclusion criteria

Exclusion:

  • Subject has any prior treatment with other treatments without adequate as defined in the protocol.
  • Subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written .
  • Subject has unresolved treatment-related toxicities from previous anticancer therapy of Grade ≥2 (with exception of vitiligo or alopecia).
  • Subject has active gastrointestinal disease or other that could interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.
  • Concurrent participation in any clinical research study involving treatment with any drug, radiotherapy, or surgery, except for the nontreatment phases of these studies (e.g., follow-up phase).

Other protocol inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
442 participants (estimated)

Study arms

  • Experimental
    D3S-001 monotherapy

    Part 1: Dose Escalation, D3S-001 administered orally. Part 2 and Part 3a Arm C: Dose Expansion, D3S-001 administered orally in selected cancer type patients. Part 4a: Dose Optimization, D3S-001 administered orally in selected cancer type patients.

    Drug: D3S-001

  • Experimental
    D3S-001 and pembrolizumab

    Part 3a Arm A: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients. Pembrolizumab administered intravenously.

    Drug: D3S-001 · Drug: Pembrolizumab

  • Experimental
    D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + pemetrexed)

    Part 3a Arm B: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients. Cisplatin + pemetrexed administered intravenously or Carboplatin + pemetrexed administered intravenously

    Drug: D3S-001 · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed

  • Experimental
    D3S-001 and Cetuximab

    Part 3b: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients. Cetuximab administered intravenously.

    Drug: D3S-001 · Drug: Cetuximab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: From first dose until 30 days after the last dose (or specified in the protocol).

  2. Number of Participants With Dose-Limiting Toxicities (DLTs)

    Time frame: From Cycle 1 Day 1 through Day 21. Each cycle is 21 days.

Secondary outcomes

  1. D3S-001 maximum observed plasma concentration (Cmax)

    Time frame: Up to 24 months.

  2. D3S-001 time to maximum plasma concentration (tmax)

    Time frame: Up to 24 months.

  3. D3S-001 half-life (t1/2)

    Time frame: Up to 24 months.

  4. D3S-001 area under the concentration-time curve (AUC)

    Time frame: Up to 24 months.

  5. Objective response rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    Time frame: Up to 24 months.

  6. Duration of Response (DOR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    Time frame: Up to 24 months.

  7. Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    Time frame: Up to 24 months.

  8. Disease Control Rate (DCR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    Time frame: Up to 24 months.

07

Study locations

51 of 52 sites recruiting
  • D3 Bio Investigative Site 0402
    Orange, California 92868, United States
    Recruiting
  • D3 Bio Investigative Site 0407
    Palo Alto, California 94304-2205, United States
    Recruiting
  • D3 Bio Investigative Site 0404
    Denver, Colorado 80218-1238, United States
    Recruiting
  • D3 Bio Investigative Site 0406
    Sarasota, Florida 34232-6410, United States
    Recruiting
  • D3 Bio Investigative Site 0401
    Detroit, Michigan 48202-2608, United States
    Recruiting
  • D3 Bio Investigative Site 0405
    Nashville, Tennessee 37203, United States
    Recruiting
  • D3 Bio Investigative Site 0403
    Houston, Texas 77030, United States
    Recruiting
  • D3 Bio Investigative Site 0102
    Sydney, New South Wales 2109, Australia
    Recruiting
  • D3 Bio Investigative Site 0101
    Malvern, Victoria 3144, Australia
    Recruiting
  • D3 Bio Investigative Site 0105
    Melbourne, Victoria 3000, Australia
    Recruiting
  • D3 Bio Investigative Site 0103
    Nedlands, Western Australia 6009, Australia
    Recruiting
  • D3 Bio Investigative Site 0104
    Bedford Park, 5042, Australia
    Recruiting
  • D3 Bio Investigative Site 0314
    Hefei, Anhui 230000, China
    Recruiting
  • D3 Bio Investigative Site 0303
    Beijing, Beijing Municipality 100036, China
    Recruiting
  • D3 Bio Investigative Site 0306
    Guangzhou, Guangdong 510120, China
    Recruiting
  • D3 Bio Investigative Site 0305
    Hangzhou, Hangzhou 310022, China
    Recruiting
  • D3 Bio Investigative Site 0307
    Harbin, Heilongjiang 150081, China
    Recruiting
  • D3 Bio Investigative Site 0309
    Wuhan, Hubei 43000, China
    Recruiting
  • D3 Bio Investigative Site 0312
    Wuhan, Hubei 430079, China
    Recruiting
  • D3 Bio Investigative Site 0315
    Changsha, Hunan 410013, China
    Recruiting
  • D3 Bio Investigative Site 0313
    Zhengzhou, Hunan 450003, China
    Recruiting
  • D3 Bio Investigative Site 0304
    Nanchang, Jiangxi 330008, China
    Recruiting
  • D3 Bio Investigative Site 0302
    Shenyang, Liaoning 110042, China
    Recruiting
  • D3 Bio Investigative Site 0310
    Jinan, Shandong 250117, China
    Recruiting
  • D3 Bio Investigative Site 0301
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
  • D3 Bio Investigative Site 0308
    Shanghai, Shanghai Municipality 201801, China
    Recruiting
  • D3 Bio Investigative Site 0316
    Chengdu, Sichuan 610041, China
    Recruiting
  • D3 Bio Investigative Site 0311
    Hangzhou, Zhejiang 310003, China
    Recruiting
  • D3 Bio Investigative Site 0804
    Bordeaux, 33000, France
    Recruiting
  • D3 Bio Investigative Site 0803
    Lyon, 69373, France
    Recruiting
  • D3 Bio Investigative Site 0801
    Rennes, 35033, France
    Recruiting
  • D3 Bio Investigative Site 0802
    Villejuif, 94805, France
    Recruiting
  • D3 Bio Investigative Site 1003
    Cologne, North Rhine-Westphalia 45147, Germany
    Recruiting
  • D3 Bio Investigative Site 1002
    Hamburg, 22297, Germany
    Recruiting
  • D3 Bio Investigative Site 0501
    Shatin, 999077, Hong Kong
    Recruiting
  • D3 Bio Investigative Site 0905
    Candiolo, 10060, Italy
    Recruiting
  • D3 Bio Investigative Site 0902
    Milan, 20141, Italy
    Recruiting
  • D3 Bio Investigative Site 0904
    Naples, 80131, Italy
    Recruiting
  • D3 Bio Investigative Site 0901
    Rome, 00144, Italy
    Recruiting
  • D3 Bio Investigative Site 0903
    Siena, 53100, Italy
    Recruiting
  • D3 Bio Investigative Site 0601
    Kashiwa, 277-8577, Japan
    Recruiting
  • D3 Bio Investigative Site 0602
    Tokyo, 104-0045, Japan
    Recruiting
  • D3 Bio Investigative Site 0204
    Cheongju-si, North Chungcheong 28644, South Korea
    Recruiting
  • D3 Bio Investigative Site 0202
    Seoul, 06591, South Korea
    Recruiting
  • D3 Bio Investigative Site 0203
    Seoul, 120-752, South Korea
    Recruiting
  • D3 Bio Investigative Site 0201
    Seoul, 138-736, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • D3 Bio Investigative Site 0706
    Barcelona, 08023, Spain
    Recruiting
  • D3 Bio Investigative Site 0701
    Barcelona, 08035, Spain
    Recruiting
  • D3 Bio Investigative Site 0704
    Madrid, 28046, Spain
    Recruiting
  • D3 Bio Investigative Site 0705
    Madrid, 28050, Spain
    Recruiting
  • D3 Bio Investigative Site 0703
    Valencia, 46010, Spain
    Recruiting
  • D3 Bio Investigative Site 0702
    Valencia, 46026, Spain
    Recruiting
08

References and documents

Publications

  • Cho BC, Lu S, Lee MA, Song Z, Park JJ, Lim SM, Li Z, Zhao J, Richardson G, Zhang Y, Zhang J, Liu A, Loong HH, Chen C, Wang J, Shen Y, Fan Z, Chen Q, Wang H, Zhang J, Chen ZJ, Johnson ML, Mok T. D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial. Nat Med. 2025 Aug;31(8):2768-2777. doi: 10.1038/s41591-025-03688-6. Epub 2025 Apr 29. PubMed 40301557 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Apr 2027, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
Jun 8, 2022
StartActual
Aug 3, 2022
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05410145
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
Aug 3, 2022
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Medical Director
Contact
D3bio_CT@d3bio.com
+86 21 61635900
Cheng Chen, MD
study director · D3 Bio (Wuxi) Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion